Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.875 CAD | -4.79% | -15.22% | +68.10% |
Mar. 27 | XORTX Therapeutics Inc. Appoints Ronald Perrone as Clinical Advisory Board | CI |
Mar. 19 | XORTX Therapeutics Provides Update | MT |
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 14.13M 19.22M |
---|---|---|---|---|---|
Net income 2023 * | -8M -10.88M | Net income 2024 * | - | EV / Sales 2023 * | - |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-1.2
x | P/E ratio 2024 * |
-
| Employees | 3 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 99.05% |
1 day | -4.79% | ||
1 week | -15.22% | ||
Current month | +18.90% | ||
1 month | +28.29% | ||
3 months | +68.69% | ||
6 months | -35.52% | ||
Current year | +68.10% |
Managers | Title | Age | Since |
---|---|---|---|
Allen Davidoff
FOU | Founder | 64 | 18-01-08 |
Jim Fairbairn
DFI | Director of Finance/CFO | 65 | 18-11-05 |
Stephen Haworth
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul van Damme
BRD | Director/Board Member | - | 18-01-24 |
Allen Davidoff
FOU | Founder | 64 | 18-01-08 |
Chairman | 67 | 22-06-05 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 4.875 | -4.79% | 7,704 |
24-03-26 | 5.12 | -1.54% | 8,183 |
24-03-25 | 5.2 | -11.86% | 13,594 |
24-03-22 | 5.9 | -9.09% | 36,625 |
24-03-21 | 6.49 | +12.87% | 66,873 |
Delayed Quote Toronto S.E., March 27, 2024 at 03:46 pm EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+68.10% | 10.4M | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.86% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |